Infectious and Inflammatory Disease Center (IIDC) and Cancer Center (CC), Sanford-Burnham Medical Research Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA.
ChemMedChem. 2012 Dec;7(12):2227-35. doi: 10.1002/cmdc.201200453. Epub 2012 Nov 8.
Successful replication of the influenza A virus requires both viral proteins and host cellular factors. In this study we used a cellular assay to screen for small molecules capable of interfering with any of such necessary viral or cellular components. We used an established reporter assay to assess influenza viral replication by monitoring the activity of co-expressed luciferase. We screened a diverse chemical compound library, resulting in the identification of compound 7, which inhibits a novel yet elusive target. Quantitative real-time PCR studies confirmed the dose-dependent inhibitory activity of compound 7 in a viral replication assay. Furthermore, we showed that compound 7 is effective in rescuing high-dose influenza infection in an in vivo mouse model. As oseltamivir-resistant influenza strains emerge, compound 7 could be further investigated as a new and potentially suitable scaffold for the development of anti-influenza agents that act on novel targets.
成功复制流感病毒需要病毒蛋白和宿主细胞因子。在这项研究中,我们使用细胞测定法筛选能够干扰任何必要病毒或细胞成分的小分子。我们使用已建立的报告基因测定法通过监测共表达的荧光素酶的活性来评估流感病毒的复制。我们筛选了多种化学化合物文库,结果鉴定出了化合物 7,它可抑制一种新颖但难以捉摸的靶标。实时定量 PCR 研究证实了化合物 7 在病毒复制测定中具有剂量依赖性的抑制活性。此外,我们表明化合物 7在体内小鼠模型中对高剂量流感感染具有有效的挽救作用。随着耐奥司他韦的流感病毒株的出现,化合物 7 可以进一步作为开发针对新型靶标的抗流感药物的新型和潜在合适的支架进行研究。